Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, prevention of exacerbations in COPD
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Oral: 200–400 mg every 6 hours; IV: 6 mg/kg loading dose over 30 minutes, then 0.4–0.6 mg/kg/h continuous infusion.
AEROLONE is not a recognized drug; no standard dosing available.
The terminal elimination half-life of theophylline is approximately 8 hours in healthy non-smoking adults (range 3-12 hours). It is prolonged in patients with hepatic cirrhosis (up to 30 hours), heart failure (up to 30 hours), and in neonates (20-30 hours). Smoking (including marijuana) decreases half-life to 4-5 hours. Half-life is shorter in children (3-5 hours). Clinical context: Due to narrow therapeutic index, half-life variability necessitates therapeutic drug monitoring.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolized to 3-methylxanthine, 1,3-dimethyluric acid, and 1-methyluric acid.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Theophylline is primarily eliminated by hepatic metabolism (>90%), with only about 10-15% excreted unchanged in urine. Renal excretion of the parent drug is minor; however, metabolites are excreted renally. Biliary/fecal excretion accounts for less than 1%.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Theophylline is approximately 40% bound to plasma proteins, primarily albumin. Protein binding is decreased in neonates, patients with hepatic disease, and in the presence of unbound fatty acids.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution (Vd) of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg). This approximates total body water. Vd is increased in premature infants (0.6-0.8 L/kg) and patients with hepatic disease. Clinical meaning: Vd is used to calculate loading dose.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 96-100% (rapidly and completely absorbed). Oral sustained-release: 80-100% depending on formulation. Rectal enema: 80-100%. Rectal suppository: 70-90%. IV: 100%.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No adjustment necessary in renal impairment as theophylline is primarily hepatically metabolized. However, in severe renal failure (Cr Cl <10 m L/min), consider reducing dose by 25%.
No data; not applicable.
Child-Pugh Class A: reduce dose by 25%; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
No data; not applicable.
Loading dose: 6 mg/kg IV; maintenance: <1 year: (0.2 x age in weeks) + 5 mg/kg/day divided q4-6h; 1-9 years: 20-24 mg/kg/day divided q4-6h; >9 years: 16 mg/kg/day divided q4-6h.
No data; not applicable.
Elderly patients >60 years: reduce maintenance dose by 25-50% due to decreased clearance; monitor serum levels closely; target 5-15 mg/L.
No data; not applicable.
None. However, close monitoring of serum theophylline levels is required due to narrow therapeutic index.
None
Serum levels must be monitored to avoid toxicity (target 5-15 mcg/m L). Use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, and elderly. Drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) can increase levels. Smoking induces metabolism leading to decreased efficacy.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component; active seizure disorder; uncontrolled cardiac arrhythmias; peptic ulcer disease (relative).
Hypersensitivity to arformoterol or any component of the formulation
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation. Charcoal-broiled foods and high-protein/low-carbohydrate diets may increase clearance of theophylline, potentially reducing efficacy.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk of minor malformations based on animal data. Second and third trimesters: No evidence of major teratogenicity; risk of fetal tachycardia and irritability due to transplacental passage; avoid high doses near term.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Excreted into breast milk with M/P ratio approximately 0.6-0.9. Infant serum levels may reach therapeutic range at maternal doses >10 mg/kg/day; monitor infant for irritability or insomnia. Generally considered compatible with breastfeeding but use lowest effective dose.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Second and third trimesters: Increased clearance due to estrogen-induced hepatic metabolism; may require dose increase by 20-40% to maintain therapeutic levels. Postpartum: Clearance returns to prepregnancy levels within 2-4 weeks; reduce dose accordingly.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
SOMOPHYLLIN (theophylline) is a narrow therapeutic index drug; monitor serum levels (therapeutic range 5-15 μg/m L for asthma). Use with caution in patients with hepatic impairment, congestive heart failure, or elderly due to reduced clearance. Cigarette smoking and charcoal-broiled foods increase clearance, requiring dose adjustment. Concurrent use with cimetidine, fluoroquinolones, or macrolides can increase levels and toxicity.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and charcoal-grilled foods as they can affect drug levels.,Avoid caffeine-containing beverages and foods (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, palpitations, or seizures.,Missed dose: take as soon as remembered unless close to next dose; do not double dose.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN vs AEROLONE, answered by our medical review team.
SOMOPHYLLIN is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN is: Oral: 200–400 mg every 6 hours; IV: 6 mg/kg loading dose over 30 minutes, then 0.4–0.6 mg/kg/h continuous infusion.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk of minor malformations based on animal data. Second and third trimesters: No evidence of major. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.